Status:
COMPLETED
A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer
Lead Sponsor:
Tang-Du Hospital
Collaborating Sponsors:
LinkDoc Technology (Beijing) Co. Ltd.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cance...
Detailed Description
The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lun...
Eligibility Criteria
Inclusion
- Patients with radical resection of lung cancer enrolled from 2014 to 2019;
- Pathologically diagnosed patients with non-small cell lung cancer;
- Patients with age \> 18 years old;
- Patients who did not receive chest surgeries before hospitalization;
- Patients with N2 lymph nodes (+) after surgeries;
- Patients who received lymphadenectomy for one group or more groups of lymph nodes;
Exclusion
- Patients with second primary tumors or multiple primary tumors;
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2018
Estimated Enrollment :
2929 Patients enrolled
Trial Details
Trial ID
NCT03451526
Start Date
December 1 2017
End Date
March 30 2018
Last Update
May 21 2018
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
2
China PLA General Hospital
Beijing, Beijing Municipality, China, 100853
3
Henan cancer hospital
Zhengzhou, Henan, China, 450008
4
Tongji Hospital Affiliated to Huazhong Technology Hospital
Wuhan, Hubei, China, 430030